CTKB vs MASS: stock comparison and AI forecast
Cytek Biosciences, Inc. (CTKB) and 908 Devices Inc. (MASS) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
CTKB Cytek Biosciences, Inc.
- Market Cap
- $750M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
MASS 908 Devices Inc.
- Market Cap
- $422M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- CTKB is 1.8 times larger than MASS by market capitalization ($750M against $422M).
- CTKB turns -39.0% of its revenue into net income, against -57.0% for MASS.
- MASS carries 0.56 times debt per unit of equity, against 0.39 times for CTKB.
- Both companies share the SEC industry classification Laboratory Analytical Instruments.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | CTKB | MASS |
|---|---|---|
| Market Cap | $750M | $422M |
| P/B Ratio | 2.33x | 3.33x |
| EPS | $-0.63 | $-0.64 |
| Book Value/Share | $2.48 | $3.07 |
| Revenue/Share | $1.59 | $1.47 |
| FCF/Share | $-0.09 | $0.01 |
Profitability & Margins
| Metric | CTKB | MASS |
|---|---|---|
| ROE | -25.0% | -27.3% |
| ROA | -18.0% | -17.5% |
| ROIC | -12.3% | -26.3% |
| Gross Margin | 53.2% | 52.2% |
| Operating Margin | -21.6% | -64.0% |
| Net Margin | -39.0% | -57.0% |
| EBT Margin | -20.2% | -56.4% |
| Tax Rate | -95.4% | 0.3% |
Financial Health
| Metric | CTKB | MASS |
|---|---|---|
| Current Ratio | 4.48x | 2.67x |
| Quick Ratio | 3.86x | 2.38x |
| D/E Ratio | 0.39x | 0.56x |
| Financial Leverage | 1.39x | 1.56x |
| Interest Coverage | -24.3x | 26.0x |
| Working Capital | $294M | $83M |
Cash Flow
| Metric | CTKB | MASS |
|---|---|---|
| Operating Cash Flow | -$6M | $1M |
| Free Cash Flow | -$12M | $610K |
| Capital Spending | -$6M | -$880K |
| OCF Growth YoY | -139.7% | – |
| FCF Growth YoY | -211.1% | – |
| FCF/Sales | -5.8% | 1.0% |
| CapEx/Sales | 2.9% | 1.4% |
Operational Efficiency
| Metric | CTKB | MASS |
|---|---|---|
| Asset Turnover | 0.46x | 0.31x |
| Receivables Turnover | 4.2x | 5.2x |
| Inventory Turnover | 1.9x | 2.0x |
| Fixed Assets Turnover | 9.9x | 13.2x |
| Days Sales Outstanding | 88 days | 70 days |
| Days Inventory | 197 days | 180 days |
| Payables Period | 0 days | 34 days |
| Cash Conversion Cycle | 285 days | 216 days |
Income Statement
| Metric | CTKB | MASS |
|---|---|---|
| Total Revenue | $207M | $61M |
| Operating Income | -$45M | -$39M |
| Net Income | -$81M | -$35M |
| R&D Expense | $37M | $14M |
| SG&A Expense | $158M | $39M |
| Cost of Goods Sold | $97M | $29M |
Dividend & Shareholder Information
| Metric | CTKB | MASS |
|---|---|---|
| Shares Outstanding | 130M | 41M |
CTKB vs MASS: stock comparison and AI forecast
Which is bigger, CTKB or MASS?
CTKB is 1.8 times larger than MASS by market capitalization ($750M against $422M).
Which one does Intratio's AI model rank higher, CTKB or MASS?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.